Business
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
CHICAGO, May 29, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling.
About this update from Tempus Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2dd3f1fdd5a6e106a480831cdadbcc52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BadmCM5mB2_1p9c4tws0.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/2dd3f1fdd5a6e106a480831cdadbcc52","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MJpnmscjZDEjzIYYn5tlnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/2dd3f1fdd5a6e106a480831cdadbcc52","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BrIa.VRLt5gcFIubsXTTCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/2dd3f1fdd5a6e106a480831cdadbcc52","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, May 29, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling.","length":490,"tagName":"p"},{"type":"text","content":"Tempus xT CDx is a 648-gene tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically Erbitux® (cetuximab) and Vectibix® (panitumumab).","length":296,"tagName":"p"},{"type":"text","content":"While xT CDx previously required a patient’s matched normal sample, this regulatory milestone allows the test to run as a tumor-only assay when a matched normal specimen (blood or saliva) is not viable or available. This approval paves the way for Tempus to migrate its entire DNA solid tumor portfolio to FDA-approved assays priced under its current ADLT (Advanced Diagnostic Laboratory Test) pricing.","length":402,"tagName":"p"},{"type":"text","content":""This approval marks a milestone in both our regulatory and ...